On July 1, 2026, a new publication involving FOXO4-DRI appeared in Naunyn-Schmiedeberg's Archives of Pharmacology. The article is titled "Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline." FOXO4-DRI remains classified as an unapproved research compound. The publication is indexed with PubMed ID 42024235 and is available through the linked source. This entry reflects only the existence and title of the publication as recorded in the journal. No specific findings, outcomes, or data from the study are described here. Readers seeking details of the research should consult the full article directly through the provided journal link. As with all research-stage compounds, FOXO4-DRI has not received regulatory approval for human use. Publication of a study does not indicate endorsement, safety determination, or efficacy conclusions beyond what is stated in the source material. This brief serves only to note that the publication has occurred and where it can be found. For further background on FOXO4-DRI, including its research status and general context, readers can consult the compound overview page.
FOXO4-DRI Study Published in Naunyn-Schmiedeberg's Archives
See the full foxo4-dri overview
Source: https://pubmed.ncbi.nlm.nih.gov/42024235/